Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Allison S. Komirenko"'
Autor:
Aristides K Maniatis, Samuel J Casella, Ulhas M Nadgir, Paul L Hofman, Paul Saenger, Elena D Chertock, Elena M Aghajanova, Maria Korpal-Szczyrska, Elpis Vlachopapadopoulou, Oleg Malievskiy, Tetyana Chaychenko, Marco Cappa, Wenjie Song, Meng Mao, Per Holse Mygind, Alden R Smith, Steven D Chessler, Allison S Komirenko, Michael Beckert, Aimee D Shu, Paul S Thornton
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(7)
Purpose The objectives of the ongoing, Phase 3, open-label extension trial enliGHten are to assess the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin in children with growth hormone deficiency. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265b429f9e88e65a20a36daf9f9774cd
https://pubmed.ncbi.nlm.nih.gov/35428884
https://pubmed.ncbi.nlm.nih.gov/35428884
Autor:
Aristides K. Maniatis, Ulhas Nadgir, Paul Saenger, Kent L. Reifschneider, Jennifer Abuzzahab, Larry Deeb, Larry A. Fox, Katie A. Woods, Wenjie Song, Meng Mao, Steven D. Chessler, Allison S. Komirenko, Aimee D. Shu, Samuel J. Casella, Paul S. Thornton
Publikováno v:
Hormone research in paediatrics. 95(3)
Introduction: The phase 3 fliGHt Trial evaluated the safety and tolerability of once-weekly lonapegsomatropin, a long-acting prodrug, in children with growth hormone deficiency (GHD) who switched from daily somatropin therapy to lonapegsomatropin. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e97f09cd230e8fa694c367e8a58be5
https://pubmed.ncbi.nlm.nih.gov/35263755
https://pubmed.ncbi.nlm.nih.gov/35263755
Autor:
Paul Saenger, Ulhas Nadgir, Paul Hofman, Paul Thornton, Elena D Chertok, Elena M Aghajanova, Maria Korpal-Szczyrska, Elpis Vlachopapadopoulou, Oleg Malievskiy, Tetyana Chaychenko, Marco Cappa, Wenjie Song, Meng Mao, Steven D Chessler, Allison S Komirenko, Michael Beckert, Aimee D Shu, Aristides K Maniatis
Publikováno v:
Journal of the Endocrine Society. 6:A645-A645
Background Once-weekly lonapegsomatropin (TransCon hGH) is a long-acting prodrug of somatropin, recently approved for the treatment of pediatric growth hormone deficiency (GHD) by the US FDA. In the pivotal 52-week phase 3 heiGHt trial and the 26-wee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2331a24785a2da58c53d2ed97ab1f12
https://doi.org/10.1210/jendso/bvac150.1334
https://doi.org/10.1210/jendso/bvac150.1334
Autor:
Florian M E, Wagenlehner, Daniel J, Cloutier, Allison S, Komirenko, Deborah S, Cebrik, Kevin M, Krause, Tiffany R, Keepers, Lynn E, Connolly, Loren G, Miller, Ian, Friedland, Jamie P, Dwyer, Robert, Poirier
Publikováno v:
The New England journal of medicine. 380(8)
The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f420104a5ea4dd1ccf657b1feac3c6
https://pubmed.ncbi.nlm.nih.gov/31398750
https://pubmed.ncbi.nlm.nih.gov/31398750
Publikováno v:
Clinical therapeutics. 41(8)
Purpose In the Phase III Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CARE), plazomicin was studied for the treatment of critically ill patients with infections caused by carbap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebae828660c31607720b6ed04d7d91c6
https://pubmed.ncbi.nlm.nih.gov/31248681
https://pubmed.ncbi.nlm.nih.gov/31248681
Autor:
Julie D. Seroogy, Allison S. Komirenko, Jacqueline A. Gibbons, Scott A. Van Wart, Valerie Riddle
Publikováno v:
Antimicrobial Agents and Chemotherapy
Plazomicin is an FDA-approved aminoglycoside for the treatment of complicated urinary tract infections. In this open-label study, 24 adults with normal renal function or mild, moderate, or severe renal impairment (n = 6 per group) received a single 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20eac70eb9596a2ba1e25ae49ceefea8
http://europepmc.org/articles/PMC6256775
http://europepmc.org/articles/PMC6256775
Publikováno v:
Clinical pharmacology in drug development. 8(6)
Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomicin is predominantly eliminated via renal pathways,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4711b744c3b6372fe98758c3d42012
https://pubmed.ncbi.nlm.nih.gov/30605260
https://pubmed.ncbi.nlm.nih.gov/30605260